Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JBNp is a proprietary nanomedicine delivery platform developed by Eascra Biotech, specifically engineered to transport mRNA therapeutics and gene-editing payloads. The platform is designed to overcome significant biological hurdles, including the ability to penetrate difficult-to-infiltrate tissue barriers such as those associated with solid tumors. A key technological advantage of JBNp is its room-temperature stability, which addresses the cold-chain logistics challenges typically associated with lipid nanoparticle (LNP) delivery systems. By enhancing the delivery of genetic material to target tissues, JBNp aims to improve the efficacy and safety profile of next-generation RNA and gene therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on JBNp.